

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 October 2003 (23.10.2003)

PCT

(10) International Publication Number
WO 03/087382 A1

- (51) International Patent Classification⁷: **C12N 15/86**
- (21) International Application Number: **PCT/GB03/01585**
- (22) International Filing Date: **11 April 2003 (11.04.2003)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
0208390.5 **11 April 2002 (11.04.2002)** **GB**
- (71) Applicant (for all designated States except US): **UNIVERSITY COLLEGE LONDON [GB/GB];** Gower Street, London WC1E 9BT (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **COFFIN, Robert, Stuart [GB/GB];** 70 Milton Street, Abington, Oxfordshire OX14 4RX (GB). **BOOTH, Matthew, James [GB/GB];** The Windeyer Institute, 46 Cleveland Street, London W1P 6DP (GB).
- (74) Agents: **WOODS, Geoffrey, Corlett et al.; J.A. Kemp & Co.,** 14 South Square, Gray's Inn, London WC1R 5JJ (GB).
- (81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.**
- (84) Designated States (regional): **ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).**
- Published:**
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **ADENO-ASSOCIATED VIRUS PRODUCER SYSTEM**

(57) Abstract: The present invention provides the use of a replication competent herpes virus which (a) lacks a functional wild-type HSV ICP27 gene; and (b) comprises an ICP27 gene encoding an ICP27 protein which allows replication of said herpes virus to occur and which has a reduced ability to inhibit RNA splicing compared to wild-type HSV ICP27 in the production of an adeno-associated virus (AAV) vector.

WO 03/087382 A1

ADENO-ASSOCIATED VIRUS PRODUCER SYSTEM**Field of the Invention**

5 The present invention relates to the use of a herpes helper virus in the production of adeno-associated virus (AAV) vectors, to a novel herpes helper virus and to an improved method of producing AAV vectors using a herpes helper virus.

Background to the Invention

10 Adeno-associated virus (AAV) vectors are promising for gene delivery and gene therapy in a number of target tissues including muscle, liver and brain. AAV is a naturally defective virus which requires a helper adenovirus or herpes virus for growth. AAV vectors are versions of AAV in which the genes encoding the necessary replication (rep) and structural (cap) proteins have been deleted to allow insertion of the sequences to
15 be delivered between the remaining terminal repeat sequences. For growth of vectors therefore, not only is a helper virus required, but the genes encoding the rep and cap proteins must be delivered to or be present in the cells used for production to provide the rep and cap functions *in trans*.

20 Such production systems have provided a problem in the field because stable cell lines expressing appropriate levels of rep and cap genes have been difficult to produce. Versions of helper adenovirus containing these genes have also not solved the problem. Thus in general for the production of AAV vectors, a plasmid encoding the rep and cap genes and a plasmid containing the DNA sequence to be packaged flanked by AAV
25 terminal repeats are transfected into cells and then the cells infected with a helper adenovirus. This process for the production of AAV vectors is relatively laborious and inefficient and is hard to scale up.

 AAV production systems using herpes simplex virus (HSV) as a helper virus are also known. An amplicon system has been described but the use of HSV as a helper virus
30 for AAV growth has to date been best accomplished using non-replicating mutants of HSV deleted for ICP27 (Conway *et al* 1999).

Summary of the Invention

The present inventors have devised a novel AAV production system which uses as a helper virus a herpes virus, preferably a herpes simplex virus (HSV), having improved properties compared to previous herpes helper viruses. When HSV is used, the novel AAV production system of the present invention uses a HSV helper virus containing an ICP27 protein which allows HSV replication to occur but which shows reduced inhibition of mRNA splicing compared to wild-type HSV-1 ICP27. The ICP27 protein may be a mutant protein which is mutated so that the usual inhibition of mRNA splicing associated with expression of ICP27 is reduced or prevented, but so that virus replication is not prevented. Alternatively, a non-HSV homologue of ICP27 with these properties may be used in the producer system of the invention.

HSV genes are in the main non-spliced while the majority of mammalian cellular genes are spliced. HSV has evolved a mechanism of enhancing the expression of HSV genes as compared to host genes by inhibiting mRNA splicing. This effect is largely mediated through the HSV ICP27 protein, a multi-functional essential gene required for virus growth and replication. The AAV rep and cap genes are multiply spliced and this splicing will therefore be inhibited in the presence of wild type HSV.

The use of a herpes helper virus capable of replicating and having a reduced property of inhibiting the splicing of mRNA in infected cells can enable an increased efficiency of production of AAV vectors to be achieved compared to the use of non-replicative HSV helper viruses which have been found to be most effective previously. This AAV vector production process may be easily scaled up and is thus useful for producing AAV vectors on an industrial scale.

Accordingly, the present invention provides:

- the use of a replication competent herpes virus which
 - (a) lacks a functional wild-type HSV ICP27 gene; and
 - (b) comprises a nucleic acid encoding an ICP27 protein, or a functional equivalent thereof from a non-HSV herpes virus, which allows replication of said herpes virus to occur and which has a reduced ability to inhibit RNA splicing compared to wild-type HSV ICP27

in the production of an adeno-associated virus (AAV) vector;

- a replication competent herpes virus which
 - (a) lacks a functional wild-type HSV ICP27 gene;
 - (b) comprises a nucleic acid encoding an ICP27 protein, or a functional equivalent thereof from a non-HSV herpes virus, which allows replication of said herpes virus to occur and which has a reduced ability to inhibit RNA splicing compared to wild-type HSV ICP27; and
 - (c) comprises AAV rep and/or cap genes and/or an AAV vector sequence;
- a method of producing an AAV vector comprising:
 - (i) introducing into producer cells:
 - (a) a herpes virus which lacks a functional wild-type HSV ICP27 gene;
 - (b) a nucleic acid encoding an ICP27 protein, or a functional equivalent thereof from a non-HSV herpes virus, which allows replication of said herpes virus to occur and which has a reduced ability to inhibit RNA splicing compared to wild-type HSV ICP27;
 - (c) AAV rep and cap genes; and
 - (d) an AAV vector sequence; and
 - (ii) isolating the AAV vector particles produced;
- an AAV vector produced by a method of the invention;
- a pharmaceutical composition comprising an AAV vector according to the invention and a pharmaceutically acceptable carrier or diluent;
- a method of producing a pharmaceutical composition comprising formulating an AAV vector according to the invention with a pharmaceutically acceptable carrier or diluent;
- a method of gene therapy comprising administering a therapeutically effective amount of an AAV vector according to the invention to a patient in need thereof; and
- a kit for producing an AAV vector comprising:
 - (a) a replication competent herpes virus which lacks a functional wild-type HSV ICP27 gene;

- (b) a nucleic acid encoding an ICP27 protein, or a functional equivalent thereof from a non-HSV herpes virus, which allows replication of said herpes virus to occur and which has a reduced ability to inhibit RNA splicing compared to wild-type HSV ICP27;
- 5 (c) AAV rep and cap genes;
- (d) an AAV vector sequence; and optionally
- (e) producer cells

wherein said nucleic acid (b), said AAV rep and cap genes (c) and/or said AAV vector sequence (d) are incorporated into said herpes virus (a), are present on

10 separate plasmids or are stably integrated into said producer cells (e).

Brief Description of the Sequence Listing

SEQ ID No. 1 is the nucleotide sequence encoding ICP27 from HSV1 (GenBank

15 Accession No. AF220940).

SEQ ID No. 2 is the amino acid sequence of ICP27 from HSV1 (GenBank Accession No. AF220940).

Detailed Description of the Invention

20

The invention provides the use of a replication competent herpes virus which

- (a) lacks a functional wild-type HSV ICP27 gene; and
- (b) comprises a nucleic acid encoding an ICP27 protein, or a functional equivalent thereof from a non-HSV herpes virus, which allows
- 25 replication of said herpes virus to occur and which has a reduced ability to inhibit RNA splicing compared to wild-type HSV ICP27

in the production of an adeno-associated virus (AAV) vector.

A herpes virus which lacks a functional wild-type HSV ICP27 may be an HSV, preferably HSV-1, HSV-2 or an intertypic recombinant HSV, in which the wild-type HSV

30 ICP27 gene has been deleted or in which the HSV ICP27 gene has been mutated such that one or more of the normal functions of the ICP27 protein is inhibited or prevented.

Alternatively the herpes virus may be a non-HSV herpes virus which naturally does not contain a wild-type HSV ICP27 gene or a non-HSV herpes virus which lacks a functional wild-type HSV ICP27 homologue.

By a "functional equivalent" it is meant a herpes virus gene that performs the same or a similar function as ICP27 in HSV and that exhibits sequence homology, at the amino acid level, to the HSV ICP27 protein. Typically, a functional equivalent of, the HSV ICP27 gene will show at least 15%, preferably at least 20%, more preferably at least 50%, at least 70%, at least 80%, at least 90%, at least 95% or at least 98% sequence identity at the amino acid level to the HSV ICP27 protein sequence shown in SEQ ID No. 2 over a region of at least 20, preferably at least 30, for instance at least 40, 60 or 100 or more contiguous amino acids, more preferably over the whole length of SEQ ID No. 2.

Methods of measuring protein and nucleotide homology are well known in the art and it will be understood by those of skill in the art that in the present context, protein homology is calculated on the basis of amino acid identity (sometimes referred to as "hard homology").

Methods of measuring nucleic acid and protein homology are well known in the art. For example the UWGCG Package provides the BESTFIT program which can be used to calculate homology (for example used on its default settings) (Devereux *et al.* (1984) *Nucleic Acids Research* 12, p387-395). The PILEUP and BLAST algorithms can be used to calculate homology or line up sequences (typically on their default settings), for example as described in Altschul (1993) *J. Mol. Evol.* 36:290-300; Altschul *et al.* (1990) *J. Mol. Biol.* 215:403-10.

Software for performing BLAST analyses is publicly available through the National Centre for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). This algorithm involves first identifying high scoring sequence pair (HSPs) by identifying short words of length W in the query sequence that either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighbourhood word score threshold (Altschul *et al.*, 1990). These initial neighbourhood word hits act as seeds for initiating searches to find HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extensions for the word hits in

each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a word length (W) of 11, the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1992) *Proc. Natl. Acad. Sci. USA* 89: 10915-10919) alignments (B) of 50, expectation (E) of 10, M=5, N=4, and a comparison of both strands.

The BLAST algorithm performs a statistical analysis of the similarity between two sequences; see e.g., Karlin and Altschul (1993) *Proc. Natl. Acad. Sci. USA* 90: 5873-5787. One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a sequence is considered similar to another sequence if the smallest sum probability in comparison of the first sequence to the second sequence is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

Homologues of the HSV ICP27 gene from other herpes viruses can be identified in a number of ways, for example by probing genomic or cDNA libraries made from the herpes virus with probes comprising all or part of the sequence shown in SEQ ID No. 1 under conditions of medium to high stringency (0.2X SSC/0.1% SDS at from about 40°C to about 55°C). Alternatively, species homologues may also be obtained using degenerate PCR which will use primers designed to target sequences within the homologues encoding conserved amino acid sequences. The primers will contain one or more degenerate positions and will be used at stringency conditions lower than those used for cloning sequences with single sequence primers against known sequences (for example, 2 x SSC at 60°C).

A homologue of the HSV ICP27 gene from a non-HSV herpes virus is typically a functional equivalent thereof. This can be confirmed by testing the functional properties of the homologue. Generally, a functional equivalent of HSV ICP27 is an immediate early gene and encodes a protein which is capable of inhibiting gene splicing, which is

essential for efficient herpes virus replication. Such functional equivalents include the equine herpes virus 1 UL3 gene, the VZV ORF4 gene and the HHV8 ORF57 gene.

The wild-type HSV ICP27 gene, or functional equivalent thereof in a non-HSV herpes virus, may be rendered functionally inactive by several techniques well known in the art. For example, they may be rendered functionally inactive by deletion(s), substitution(s) or insertion(s), preferably by deletion. Deletions may remove portions of the genes or the entire gene. For example, deletion of only one nucleotide may be made, resulting in a frame shift. However, preferably larger deletions are made, for example at least 25%, more preferably at least 50% of the total coding and non-coding sequence (or alternatively, in absolute terms, at least 10 nucleotides, more preferably at least 100 nucleotides, most preferably, at least 1000 nucleotides). It is particularly preferred to remove the entire gene and some of the flanking sequences. Inserted sequences may include the nucleic acid encoding an ICP27 protein or functional equivalent thereof having impaired RNA splicing inhibitory activity but which allows herpes virus replication to occur.

Mutations may be made in the herpes viruses by homologous recombination methods well known to those skilled in the art. For example, HSV genomic DNA is transfected together with a vector, preferably a plasmid vector, comprising the mutated sequence flanked by homologous HSV sequences. The mutated sequence may comprise deletion(s), insertion(s) or substitution(s), all of which may be constructed by routine techniques. Insertions may include selectable marker genes, for example lacZ, for screening recombinant viruses by, for example, β -galactosidase activity.

The nucleic acid encoding an ICP27 protein which protein allows herpes virus replication to occur and which has a reduced ability to inhibit RNA splicing compared to wild-type HSV ICP27, or functional equivalent thereof from a non-HSV herpes virus is preferably operably linked to promoter sequence permitting expression of the ICP27 protein in producer cells. Any suitable promoter sequence may be used, for example an immediate early gene promoter. Preferably the promoter sequence is an ICP27 promoter, such as an HSV-1 or HSV-2 ICP27 promoter. More preferably, the promoter is the endogenous ICP27 promoter in HSV or the endogenous promoter of an ICP27 homologue in a non-HSV herpes virus. Alternatively, the promoter may be a mammalian promoter,

such as a promoter of mammalian or viral origin active in mammalian cells. Examples of suitable mammalian promoters include the CMV, RSV, MMLV or SV40 promoters.

The ICP27 protein in the herpes virus is typically an HSV ICP27 protein which contains a mutation that prevents the ICP27 protein from inhibiting RNA splicing or which reduces the level of inhibition of RNA splicing compared to wild-type HSV ICP27 protein. The mutation of the ICP27 protein does not prevent replication of the herpes virus. However, replication of the herpes virus may be less efficient than replication of the parent herpes virus which comprises a wild-type ICP27 gene, or functional equivalent thereof. Herpes virus replication may be monitored by any suitable method, for example by infecting host cells with the herpes virus comprising the ICP protein, or functional equivalent thereof, and determining the virus titre after a period of incubation, for example for 24 to 48 hours.

A herpes helper virus of the invention has a reduced property of inhibiting the splicing of mRNA in infected cells. Inhibition of RNA splicing by the ICP27 protein may be reduced by 10, 20, 30 or 40%, preferably by 50, 60, 70, 80 or 90% compared to wild-type HSV ICP27 protein, for example to wild-type HSV-1 or HSV-2 ICP27 protein. Any suitable assay for monitoring RNA splicing may be used to determine whether an ICP27 protein has a reduced ability to inhibit RNA splicing. For example, RNA splicing may be monitored by northern blotting or RNase protection assays to determine the relative levels of spliced and unspliced transcripts present. Typically RNA splicing assays are carried out both in the presence and absence of wild-type HSV ICP27 and in the presence and absence of the ICP27 protein, or functional equivalent thereof being tested. RNA splicing in the presence of the wild-type HSV1 ICP27 protein may be compared to RNA splicing in the presence of the ICP27 protein, or functional equivalent thereof, being tested to determine whether the test protein has a reduced ability to inhibit RNA splicing.

A herpes helper virus of the invention thus allows more mRNA splicing to occur in infected cells than can occur in cells infected with a herpes virus comprising a wild-type HSV ICP27 gene. Preferably the herpes virus of the invention allows a significant amount of mRNA splicing to occur in infected cells, i.e. the inhibition of gene splicing the ICP27 protein encoded by the herpes helper virus is negligible. RNA splicing in cells infected with a virus of the invention may be uninhibited or be inhibited by 1, 5, 10, 20,

30, 40, 50, 60, 70 or 80% compared to RNA splicing in cells not infected with a herpes virus.

The nucleic acid encoding the ICP27 protein may be mutated so that its ability to inhibit gene splicing is impaired by any technique well known in the art, for example, by deletion(s), substitution(s) or insertion(s) into the portion(s) of the gene important for the inhibition of gene splicing. It is not desirable to delete large portions of the ICP27 gene because it is necessary that the gene retains its ability to enable herpes virus replication to occur. However, small deletions, insertions and/or substitutions may be made as appropriate to diminish the gene splicing-inhibitory activity. Examples of mutant ICP27 proteins are described in Soliman *et al.* 1997.

Typically, the ICP27 mutant protein may have one or more mutation in the KH3 domain and/or the SM motif. Preferred mutant ICP27 have one or more mutation in the region from amino acids 400 to 512 of SEQ ID No. 2, such as between amino acids 450 and 490, amino acids 470 and 500 or amino acids 480 and 500. The mutation may be a C-terminal truncation of the ICP27 protein sequence shown in SEQ ID No. 2. More preferably, the amino acid at position 480 of SEQ ID No. 2 is mutated. The amino acids at positions 334, 487 and/or 496 of SEQ ID NO: 2 may alternatively or additionally be mutated. For example, the ICP27 protein may comprise an R480H substitution and an L334S substitution or an R480H substitution and a V487I substitution. Most preferably, the ICP27 protein is the double mutant R480H/ V496I.

Alternatively, the ICP27 protein may be a functional equivalent of HSV ICP27 from a non-HSV herpes virus, which functional equivalent does not inhibit RNA splicing, or shows reduced inhibition of RNA splicing compared to wild-type HSV ICP27 protein, and which does not prevent the herpes virus from replicating. The functional equivalent may be a wild-type (native) protein from a non-HSV herpes virus or may be a mutant protein. Where the functional equivalent is a mutant protein the mutation typically corresponds to one of the mutations mentioned herein with respect to the HSV ICP27 protein. Corresponding mutations may be determined by aligning the amino acid sequence of the functional equivalent to that of SEQ ID No. 2 using any suitable alignment technique.

The herpes virus may additionally comprise AAV rep and/or cap genes. The rep and/or cap genes are preferably inserted into a site or sites of the herpes virus genome such that replication of the herpes virus is not prevented. Suitable sites of insertion include the UL43, US5 and LAT loci but other insertion sites may also be used. The rep and cap genes comprise the coding sequences of the rep and cap genes from an AAV operably linked to control sequences. Any suitable control sequences may be used. For example, the rep and cap genes may be under the control of herpes virus promoters. Preferably, the control sequences are the promoters which usually control rep and cap expression in AAV.

10 The herpes virus may comprise an AAV vector sequence. The AAV vector sequence is preferably inserted into a site or sites of the herpes virus genome such that replication of the herpes virus is not prevented. Suitable sites of insertion include the UL43, US5 and LAT loci but many other insertion sites may also be used.

The AAV vector sequence is typically a DNA sequence to be packaged flanked by AAV terminal repeats. The DNA sequence to be packaged is generally an expression cassette comprising a sequence encoding a heterologous protein operably linked to a control sequence. It is preferred that the heterologous protein is a therapeutic protein.

The invention also provides a herpes virus which

- (a) lacks a functional wild-type HSV ICP27 gene;
- 20 (b) comprises a nucleic acid encoding an ICP27 protein, or a functional equivalent thereof from a non-HSV herpes virus, which allows replication of said herpes virus to occur and which has a reduced ability to inhibit RNA splicing compared to wild-type HSV ICP27;
- 25 (c) an AAV cap gene and/or an AAV rep gene; and/or
- (d) an AAV vector sequence.

A herpes virus of the invention is preferably HSV-1 or HSV-2 or an intertypic recombinant virus containing DNA from HSV-1 and HSV-2 strains. A herpes virus of the invention may be a non-HSV virus which further lacks a functional wild-type HSV ICP27 homologue. The nucleic acid (b) and the AAV sequences (c) and (d) are as defined above.

30

A further aspect provided by the present invention is a method of producing an AAV vector comprising:

- (i) introducing into producer cells:
 - (a) a herpes virus which lacks a functional wild-type HSV ICP27 gene;
 - 5 (b) a nucleic acid encoding an ICP27 protein, or a functional equivalent thereof from a non-HSV herpes virus, which allows replication of said herpes virus to occur and which has a reduced ability to inhibit RNA splicing compared to wild-type HSV ICP27;
 - (c) AAV rep and cap genes; and
 - 10 (d) an AAV vector sequence; and
- (ii) isolating the AAV vector particles produced.

The nucleic acid encoding an ICP27 protein (b) is as defined above. The nucleic acid may be incorporated into the herpes virus (a). Alternatively, the nucleic acid is not incorporated into the herpes virus but is present in the producer cells such that it can
15 complement the lack of HSV ICP27 gene in the herpes virus *in trans*. The nucleic acid may be introduced into the producer cells by transient transfection of a plasmid into the producer cells either before or after the cells are infected with HSV. In a preferred embodiment of the invention the nucleic acid is stably integrated into the genome of the producer cells. Suitable methods of transient and stable transfection are well known in
20 the art.

Where the nucleic acid encoding the ICP27 protein is introduced into the producer cells by transient or stable transfection, there is preferably no overlap between the nucleotide sequences in the plasmid or cell line and the nucleotide sequences of the herpes virus, thus preventing homologous recombination. Prevention of homologous
25 recombination is important in order to prevent the generation of a herpes virus which can replicate in the absence of the producer cells. The AAV particles produced by such a method will therefore be free from any contaminating replication competent herpes virus.

The AAV rep and/or cap genes (c) and/or the AAV vector sequence (d) may be incorporated into the herpes virus (a). The rep and/or cap genes and/or AAV vector
30 sequences are preferably inserted into a site or sites of the herpes virus genome such that

replication of the herpes virus is not prevented. Suitable sites of insertion include the UL43, US5 and LAT loci but many other insertion sites may also be used.

Alternatively the AAV rep and/or cap genes (c) and/or the AAV vector sequence (d) may each be introduced into the cells by transient or stable transfection of suitable plasmids. Suitable methods of transfection are well known in the art. When transient transfection is used to introduce the AAV rep and/or cap genes and/or the AAV vector sequence into the producer cells, the transfection may be carried out before or after infection of the cells with the herpes virus. If stable transfection is used, it is preferable that the AAV rep and/or cap genes and/or AAV vector sequences are integrated into the producer cell genome prior to infection of the producer cells with the herpes virus.

Producer cells used in the invention include any cell line that supports the growth of the herpes virus. A suitable cell line is a cell line which hosts herpes viruses and forms colonies. Typically the cell line is a mammalian cell line such as a rodent or human cell line. A particularly preferred cell line is based on BHK or Vero cells.

In a further aspect, the present invention provides a kit for producing an AAV vector comprising:

- (a) a replication competent herpes virus which lacks a functional wild-type HSV ICP27 gene;
- (b) a nucleic acid encoding an ICP27 protein, or a functional equivalent thereof from a non-HSV herpes virus, which allows replication of said herpes virus to occur and which has a reduced ability to inhibit RNA splicing compared to wild-type HSV ICP27;
- (c) AAV rep and cap genes;
- (d) an AAV vector sequence; and optionally
- (e) producer cells

wherein (b), (c) and/or (d) are incorporated into said herpes virus (a), are present on separate plasmids or are stably integrated into said producer cells (e).

In a further aspect of the invention is provided an AAV vector produced by a method of the invention, produced using a herpes virus of the invention or using a kit of the invention. The AAV vector is typically lacking rep and cap genes and comprises a heterologous gene, i.e. a sequence encoding a heterologous protein, operably linked to

control sequences. The heterologous protein is preferably a therapeutic protein. A therapeutic protein is defined herein as being a protein which it is desirable to introduce into a cell or cells of a patient in order to treat a disease or disorder.

An AAV vector of the invention may be formulated with a pharmaceutically acceptable carrier or diluent and/or may be administered to a patient in a method of treatment of a disease or disorder, for example by gene therapy.

Accordingly, the present invention provides a pharmaceutical composition for use in a method of treatment such as gene therapy comprising an AAV vector according to the invention and a pharmaceutically acceptable carrier or diluent. A method of producing a pharmaceutical composition by admixing an AAV vector of the invention with a pharmaceutically acceptable carrier or diluent is also provided.

A method of treatment of the human or animal body, for example a method of gene therapy, comprising administering a therapeutically effective amount of an AAV vector of the invention to a patient in need thereof. A therapeutically effective amount of an AAV vector is an amount which enables a therapeutic gene in the vector to be expressed in cells of a patient at a level that alleviates the symptoms of the disease or disorder to be treated or that improves the condition of the patient. A patient in need of treatment is a patient suffering from or predisposed to a disease or disorder that can be treated by administration of a therapeutic gene incorporated into an AAV vector.

The invention is illustrated by the following preferred embodiments:

Embodiment 1

- (i) The HSV helper virus has the wild type HSV ICP27 gene replaced with a mutant version of ICP27 with which the inhibition of splicing is reduced but which can still support the replication of HSV. Examples of such mutations have been reported previously (Soliman *et al.* 1997). Alternatively the wild type ICP27 gene is replaced with a non-HSV homologue of ICP27 which supports virus growth but which displays a reduced inhibition of splicing as compared to HSV ICP27;
- (ii) Plasmids encoding the AAV vector sequences and the AAV rep and cap genes are stably or transiently transfected into cells which can support the growth of HSV. In the

case of stable transfection, these cells are then infected with helper viruses as described in (i) above. In the case of transient transfection, cells are infected with the helper virus before, at the same time as, or after transfection. Experiment will determine the optimal timing for this;

- 5 (iii) AAV vector particles are produced.

Embodiment 2

- 10 (i) The HSV helper virus has the wild type HSV ICP27 gene replaced with a mutant version of ICP27 with which the inhibition of splicing is reduced but which can still support the growth of HSV. Examples of such mutations have been reported previously (Soliman *et al.* 1997). Alternatively the wild type ICP27 gene is replaced with a non-HSV homologue of ICP27 which supports virus growth but which displays a reduced inhibition of splicing as compared to HSV ICP27;
- 15 (ii) Any of the AAV rep, cap or vector sequences to be packaged are incorporated into the helper virus described above, reducing the number of plasmids required to be stably or transiently transfected into the producer cells, prior to use for AAV vector production; and
- (iii) AAV vector particles are produced

20

- In a particularly preferred version of embodiment 2, the helper virus is an HSV in which the wild-type HSV ICP27 gene has been replaced with a mutant HSV-1 ICP27 gene. The mutant HSV-1 ICP27 gene is capable of supporting virus growth but shows a reduced inhibition of splicing compared to wild type HSV-1 ICP27 is constructed. The mutant HSV-1 ICP27 gene may be a mutant as described in Soliman *et al.* 1997. The rep and cap encoding sequences from AAV are inserted into the HSV helper virus. The site or sites of insertion of the rep and cap genes is chosen so that HSV replication is not prevented. Suitable sites include the UL43, US5 or LAT loci, but many others are possible. The HSV helper virus is used to infect cells, such as BHK or Vero cells, which support the growth of HSV in which the AAV vector sequence is stably integrated into the cellular genomic DNA. AAV vector particles are then produced.
- 30

In a second preferred version of embodiment 2, the HSV helper virus is identical to that used in the first preferred version except that in addition to the rep and cap encoding sequences from AAV, the AAV vector sequence is inserted into the HSV helper virus. The site of insertion of the AAV vector sequence is chosen so that HSV replication is not prevented. Suitable sites include the UL43, US5 or LAT loci, but many others are possible. The HSV helper virus is used to infect cells, such as BHK or Vero cells, which support the growth of HSV. AAV vector particles are then produced.

Embodiment 3

10

- (i) The HSV helper virus has the wild type HSV ICP27 gene mutated such that no replication is possible in cells which do not complement the deficiency.
- (ii) The cells used for production contain a version of ICP27 with which the inhibition of splicing is reduced but which can still support the growth of HSV introduced by stable or transient transfection. Alternatively a non-HSV homologue of ICP27 which supports virus growth but which displays a reduced inhibition of splicing as compared to HSV ICP27 is used;
- (iii) AAV rep and cap and vector sequences are introduced and helper virus provided as in Embodiments 1 or 2 above; and
- (iv) AAV vector particles are produced.

20

The following Examples illustrate the invention.

Example 1: Virus Construction

25

Six viruses were constructed in order to test the hypothesis that use of a virus with a mutated ICP27 gene in which inhibition of splicing was reduced was more effective at producing AAV than HSV with wild type ICP27 or HSV with ICP27 deleted.

1. 17+/UL43/repcap

This virus contains the AAV rep and cap genes inserted into the UL43 gene of wild type HSV1 strain 17+. UL43 is a non-essential HSV gene the mutation of which does not affect replication (Maclean *et al*). The virus was constructed by inserting the repcap gene excised from pdeltaBal (supplied by Dr Adrian Thrasher, University College London) into the unique NsiI site of the UL43 gene.

2. 17+/US5/AAVGFP

This virus contains the AAV ITRs flanking a CMV-GFP-bGH polyA cassette inserted into the US5 gene of wild type HSV1 strain 17+. US5 is a non-essential HSV gene the mutation of which does not affect replication (Balan *et al*).

3. 17+mut.27/UL43/repcap

This virus contains the AAV rep and cap genes inserted into the UL43 gene of a derivative of HSV1 strain 17+ in which the ICP27 gene has been mutated to include the R480H/V496I double mutation described in Soliman *et al*. This mutation has previously been shown to allow improved splicing as compared to wild type ICP27 (Soliman *et al*). The virus was constructed by inserting the repcap gene excised from pdeltaBal (supplied by Dr Adrian Thrasher, University College London) into the unique NsiI site of the UL43 gene of a virus in which the ICP27 gene had been replaced with a mutant gene in which a double point mutation (R480H/V496I; Soliman *et al*) had been inserted using the Stratagene Quickchange XL kit.

4. 17+mut.27/US5/AAVGFP

This virus contains the AAV ITRs flanking a CMV-GFP-bGH polyA cassette inserted into the US5 gene of HSV1 strain 17+ in which the ICP27 gene has been mutated according to Soliman *et al*, as above.

-17-

5. 17+27-/UL43/repcap

This virus contains the AAV rep and cap genes inserted into the UL43 gene of a derivative of HSV1 strain 17+ in which the ICP27 gene has been deleted. The virus was constructed by inserting the repcap gene excised from pdeltaBal (supplied by Dr Adrian Thrasher, University College London) into the unique NsiI site of the UL43 gene of 17+27-.

6. 17+27-/US5/AAVGFP

10

This virus contains the AAV ITRs flanking a CMV-GFP-bGH polyA cassette inserted into the US5 gene of HSV1 strain 17+ in which the ICP27 gene has been deleted, as above.

15 Example 2: Production of AAV

Viruses 1 & 2, 3 & 4, or 5 & 6 were tested for AAV production using the following procedure:

- 20 1) BHK or B130 cells (Howard *et al*) (175cm² flask) were infected with the appropriate pair of viruses at a range of MOIs and incubated at 37°C for 2 days. B130 cells are BHK cell which contain the HSV1 ICP27 gene allowing the growth of HSV1 deleted for ICP27 (Howard *et al* Gene Ther. 1998 Aug; 5(8):1137-47.)
- 25 2) Cells were harvested 2 days p.i. using a cell scraper, transferred to a 50ml Falcon tube and spun at 1000rpm for 10 min.
- 3) The supernatant was removed and the pellet resuspended in 1ml TMN buffer (50 mM Tris pH 8.0, 5 mM MgCl₂, 0.15M NaCl).

30

-18-

- 4) Three cycles of freeze thawing was carried out using dry ice and a 37°C water bath, vortexing thoroughly between cycles.
- 5) 50U benzonase was then added to the lysate and incubated for 30 min at 37°C.
- 5 6) The lysate was clarified by centrifugation at 4000rpm for 20 min and the supernatant containing AAV was removed and stored at -20°C.
- 7) AAV preparations were titred for capsid number using Progen's AAV titration
10 ELISA kit (Cat. No. PRATV)

The results of this experiment are set out in the Table 1 below.

Table 1: AAV production using different HSV viruses

Virus (a)	Virus (b)	MOI used	Cell type	AAV Capsid titre (particles/ml)
17+/UL43/repcap	17+/US5/AAVGFP	0.5 0.05 0.005	BHK	1.2×10^6 2.4×10^8 1.7×10^8
17+mut.27/UL43/repcap	17+mut.27/US5/AAVGFP	0.5 0.05 0.005	BHK	1.9×10^{10} 1.8×10^{10} 1.8×10^{10}
17+27-/UL43/repcap	17+27-/US5/AAVGFP	5 0.5 0.05 0.005	BHK	2.0×10^{10} 2.1×10^{10} 8.0×10^9 6.2×10^6
17+27-/UL43/repcap	17+27-/US5/AAVGFP	5 0.5 0.05 0.005	B130	6×10^8 5.6×10^8 6.2×10^8 1.1×10^8

This shows that while all three sets of viruses can be used for the production of AAV, HSV with an intact ICP27 gene is less effective than HSV in which ICP27 is deleted or mutated. This is presumably because the ICP27 produced from the intact ICP27 gene inhibits splicing of AAV transcripts.

Where ICP27 is deleted, the use of cells in which the virus cannot replicate (BHK cells) provides greater yields of AAV than does the use of cells in which replication can occur (B130 cells).

Therefore, where ICP27 is deleted using BHK cells, yields which are initially high reduce as MOI is reduced, as the input virus cannot replicate. Using cells where the virus can replicate (B130 cells) only low yields are generated at any MOI, presumably as splicing is inhibited by the ICP27 produced from the B130 cells.

The viruses with ICP27 mutated produce high yields of AAV on BHK cells where the virus can replicate, better than the viruses in which ICP27 is not altered presumably as inhibition of splicing is reduced. Moreover these high yields are maintained as the MOI reduces better than is the case with the ICP27 deleted viruses, presumably because yield is maintained through virus replication.

As has previously been shown to be the case, HSV can be used for the production of AAV vectors (e.g. Conway *et al*). We have shown that the use of a replication competent virus containing a mutated ICP27 with which inhibition of splicing is reduced

-20-

allows enhanced production of AAV at low MOI as compared to HSV in which ICP27 is deleted or in which ICP27 is in tact. Use of HSV with mutated ICP27 therefore provides advantages for AAV production as reduced MOI can be used which will be advantageous for the scale up of HSV-based AAV production systems.

5

References

- Conway *et al.*, 1999, Gene Therapy 6, 986-993
Soliman *et al.*, 1997, J. Virology 71, 9188-9197
Maclean *et al.*, 1991. J Gen Virol. 72 (Pt 4):897-906
10 Balan *et al.*, 1994, J Gen Virol. 75 (Pt 6):1245-58
Howard *et al.*, 1998, Gene Ther. 5(8):1137-47

CLAIMS

1. Use of a replication competent herpes virus which
 - (a) lacks a functional wild-type HSV ICP27 gene; and
 - (b) comprises a nucleic acid encoding an ICP27 protein, or a functional equivalent thereof from a non-HSV herpes virus, which allows replication of said herpes virus to occur and which has a reduced ability to inhibit RNA splicing compared to wild-type HSV ICP27 in the production of an adeno-associated virus (AAV) vector.
2. Use according to claim 1 wherein said herpes virus is HSV-1 or HSV-2.
3. Use according to claim 1 or 2 wherein said ICP27 protein is a functional equivalent of ICP27 from a non-HSV herpes virus.
4. Use according to claim 3 wherein said functional equivalent is mutated.
5. Use according to any one of the preceding claims wherein said ICP27 protein is a mutant HSV ICP27 protein.
6. Use according to claim 5 wherein the mutant protein is an HSV ICP27 protein comprising an R480H/V496I double mutation.
7. Use according to any one of the preceding claims wherein the herpes virus is not an HSV which further lacks its wild-type functional equivalent of the HSV ICP27 gene.
8. Use according to any one of the preceding claims wherein the herpes virus further comprises AAV rep and cap genes.
9. Use according to any one of the preceding claims wherein the herpes virus further comprises an AAV vector sequence.
10. Use according to claim 8 or 9 wherein said AAV rep and cap genes and/or said AAV vector sequence are inserted into the UL43 locus, US5 locus or LAT locus of said herpes virus.
11. A replication competent herpes virus as defined in any one of claims 8 to 10.
12. A method of producing an AAV vector comprising:

-22-

- (i) introducing into producer cells:
- (a) a herpes virus which lacks a functional wild-type HSV ICP27 gene;
 - (b) comprises a nucleic acid encoding an ICP27 protein, or a functional equivalent thereof from a non-HSV herpes virus, which allows replication of said herpes virus to occur and which has a reduced ability to inhibit RNA splicing compared to wild-type HSV ICP27;
 - (c) AAV rep and cap genes; and
 - (d) an AAV vector sequence; and
- (ii) isolating the AAV vector particles produced.

13. A method according to claim 12 wherein said herpes virus (a) comprises said nucleic acid (b).

14. A method according to claim 12 wherein said nucleic acid (b) is stably or transiently infected into said producer cells.

15. A method according to any one of claims 12 to 14 wherein said AAV rep and cap genes (c) and/or said AAV vector sequence (d) are inserted into said herpes virus (a).

16. A method according to claim 15 wherein said AAV rep and cap genes (c) and/or said AAV vector sequence (d) are inserted into the UL43 locus, US5 locus or LAT locus of said herpes virus.

17. A method according to any one of claims 12 to 14 wherein said AAV rep and cap genes and/or said AAV vector sequence (d) are stably or transiently transfected into said producer cells.

18. A method according to claim 14 or 17 wherein said producer cells are stably transfected prior to infection with said herpes virus (a).

19. A method according to claim 14 or 17 wherein said producer cells are transiently transfected before infection with said herpes virus (a).

20. A method according to claim 14 or 17 wherein said producer cells are transiently transfected after infection with said herpes virus (a).

21. A method according to any one of claims 12 to 17 wherein the

producer cells are BHK or Vero cells.

22. An AAV vector produced by a method of any one of claims 12 to 21.

23. A pharmaceutical composition comprising an AAV vector according to claim 20 and a pharmaceutically acceptable carrier or diluent

5 24. A method of producing a pharmaceutical composition comprising mixing an AAV vector according to claim 22 with a pharmaceutically acceptable carrier or diluent.

25. A method of producing a pharmaceutical composition comprising carrying out the method of any one of claims 12 to 21 and formulating said isolated AAV vector particles with a pharmaceutically acceptable carrier or diluent.

10 26. A method of gene therapy comprising administering a therapeutically effective amount of an AAV vector according to claim 22 to a patient in need thereof.

27. A kit for producing an AAV vector comprising:

(a) a replication competent herpes virus which lacks a functional wild-type HSV ICP27 gene;

15 (b) a nucleic acid encoding an ICP27 protein, or a functional equivalent thereof from a non-HSV herpes virus, which allows replication of said herpes virus to occur and which has a reduced ability to inhibit RNA splicing compared to wild-type HSV ICP27;

(c) AAV rep and cap genes;

20 (d) an AAV vector sequence; and optionally

(e) producer cells

wherein said nucleic acid (b), said AAV rep and cap genes (c) and/or said AAV vector sequence (d) are incorporated into said herpes virus (a), are present on separate plasmids or are stably integrated into said producer cells (e).

SEQUENCE LISTING

<110> UNIVERSITY COLLEGE LONDON

<120> ADENO-ASSOCIATED VIRUS PRODUCER SYSTEM

<130> N.85297A

<150> GB 0208390.5

<151> 2002-04-11

<160> 2

<170> PatentIn version 3.1

<210> 1

<211> 1539

<212> DNA

<213> Herpes simplex virus

<400> 1

atggcgactg acattgatat gctaattgac ctcggccttg acctctccga cagcgatctg	60
gacgaggacc ccccgagacc ggccggagagc cgccgcgacg acctggaatc ggacagcaac	120
ggggagtgtt cctcgtcgga cgaggacatg gaagaccccc acggagagga cggaccggag	180
ccgatactcg acgccgctcg cccggcggtc cgcccgcttc gtccagaaga ccccggcgta	240
cccagcacc cagacgctcg tccgacggag cggcagggcc ccaacgatcc tcaaccagcg	300
ccccacagtg tgtgtcgcg cctcggggcc cggcgaccgt cttgctcccc cgagcggcac	360
gggggcaagg tggcccgctt ccaaccccc cccgaccaaag cccagcctgc ccgcgcgga	420
cgccgtgggc gtcgcagggg tcggggtcgc ggtggtcccg gggccgccga tggtttgcg	480
gacccccgcc ggcgtgcccc cagaaccaat cgcaaccg ggggaccccg ccccgggcg	540
gggtggacgg acggccccg cgcccccat ggcgaggcgt ggcgcggaag tgagcagccc	600
gacccacccg gagggccg cgacacggagc gtgcgccaag cccccccc gctaattgacg	660
ctggcgattg ccccccgcc cgcgacccc cgcgccccg ccccgagcgc aaaggcgccc	720
gccgccgaca ccatcgacgc caccacgcgg ttggtcctgc gctccatctc cgagcgcgcg	780
gcggtcgacc gcatcagcga gagcttcggc cgcagcgcac aggtcatgca cgacccttt	840
ggggggcagc cgtttccgc cggaatagc ccctgggccc cgggtgctggc gggccaagga	900
gggccctttg acgccgagac cagacgggtc tcctgggaaa ccttggtcgc ccacggccc	960
agcctctatc gcacttttgc cggcaatcct cgggcccgcg cgaccgcaa ggccatgcgc	1020
gactgcgtgc tgcgccaaga aaatttcacg gaggcgctgg cctccgccga cgagacgctg	1080
gcgtggtgca agatgtgcat ccaccacaac ctgccgctgc gccccagga cccattatc	1140
gggacggccg cggcggtgct ggataacctc gccacgcgcc tgcggccctt tctccagtgc	1200
tacctgaagg cgcgaggcct gtgcggcctg gacgaactgt gttcgcggcg gcgtctggcg	1260

2

gacattaagg acattgcatc cttcgtgttt gtcattctgg ccaggctcgc caaccgcgtc 1320
gagcgtggcg tcgcggagat cgactacgcg acccttggtg tcggggtcgg agagaagatg 1380
catttctacc tccccggggc ctgcatggcg ggcctgatcg aaatcctaga cacgcaccgc 1440
caggagtgtt cgagtcgtgt ctgcgagttg acggccagtc acatcgtcgc cccccgtac 1500
gtgcacggca aatattttta ttgcaactcc ctgttttag 1539

<210> 2
<211> 512
<212> PRT
<213> Herpes simplex virus

<400> 2

Met Ala Thr Asp Ile Asp Met Leu Ile Asp Leu Gly Leu Asp Leu Ser
1 5 10 15
Asp Ser Asp Leu Asp Glu Asp Pro Pro Glu Pro Ala Glu Ser Arg Arg
20 25 30
Asp Asp Leu Glu Ser Asp Ser Asn Gly Glu Cys Ser Ser Ser Asp Glu
35 40 45
Asp Met Glu Asp Pro His Gly Glu Asp Gly Pro Glu Pro Ile Leu Asp
50 55 60
Ala Ala Arg Pro Ala Val Arg Pro Ser Arg Pro Glu Asp Pro Gly Val
65 70 75 80
Pro Ser Thr Gln Thr Pro Arg Pro Thr Glu Arg Gln Gly Pro Asn Asp
85 90 95
Pro Gln Pro Ala Pro His Ser Val Trp Ser Arg Leu Gly Ala Arg Arg
100 105 110
Pro Ser Cys Ser Pro Glu Arg His Gly Gly Lys Val Ala Arg Leu Gln
115 120 125
Pro Pro Pro Thr Lys Ala Gln Pro Ala Arg Gly Gly Arg Arg Gly Arg
130 135 140
Arg Arg Gly Arg Gly Arg Gly Gly Pro Gly Ala Ala Asp Gly Leu Ser
145 150 155 160
Asp Pro Arg Arg Arg Ala Pro Arg Thr Asn Arg Asn Pro Gly Gly Pro
165 170 175
Arg Pro Gly Ala Gly Trp Thr Asp Gly Pro Gly Ala Pro His Gly Glu
180 185 190
Ala Trp Arg Gly Ser Glu Gln Pro Asp Pro Pro Gly Gly Pro Arg Thr
195 200 205
Arg Ser Val Arg Gln Ala Pro Pro Pro Leu Met Thr Leu Ala Ile Ala
210 215 220
Pro Pro Pro Ala Asp Pro Arg Ala Pro Ala Pro Glu Arg Lys Ala Pro
225 230 235 240
Ala Ala Asp Thr Ile Asp Ala Thr Thr Arg Leu Val Leu Arg Ser Ile
245 250 255

3

Ser Glu Arg Ala Ala Val Asp Arg Ile Ser Glu Ser Phe Gly Arg Ser
 260 265 270
 Ala Gln Val Met His Asp Pro Phe Gly Gly Gln Pro Phe Pro Ala Ala
 275 280 285
 Asn Ser Pro Trp Ala Pro Val Leu Ala Gly Gln Gly Gly Pro Phe Asp
 290 295 300
 Ala Glu Thr Arg Arg Val Ser Trp Glu Thr Leu Val Ala His Gly Pro
 305 310 315 320
 Ser Leu Tyr Arg Thr Phe Ala Gly Asn Pro Arg Ala Ala Ser Thr Ala
 325 330 335
 Lys Ala Met Arg Asp Cys Val Leu Arg Gln Glu Asn Phe Ile Glu Ala
 340 345 350
 Leu Ala Ser Ala Asp Glu Thr Leu Ala Trp Cys Lys Met Cys Ile His
 355 360 365
 His Asn Leu Pro Leu Arg Pro Gln Asp Pro Ile Ile Gly Thr Ala Ala
 370 375 380
 Ala Val Leu Asp Asn Leu Ala Thr Arg Leu Arg Pro Phe Leu Gln Cys
 385 390 395 400
 Tyr Leu Lys Ala Arg Gly Leu Cys Gly Leu Asp Glu Leu Cys Ser Arg
 405 410 415
 Arg Arg Leu Ala Asp Ile Lys Asp Ile Ala Ser Phe Val Phe Val Ile
 420 425 430
 Leu Ala Arg Leu Ala Asn Arg Val Glu Arg Gly Val Ala Glu Ile Asp
 435 440 445
 Tyr Ala Thr Leu Gly Val Gly Val Gly Glu Lys Met His Phe Tyr Leu
 450 455 460
 Pro Gly Ala Cys Met Ala Gly Leu Ile Glu Ile Leu Asp Thr His Arg
 465 470 475 480
 Gln Glu Cys Ser Ser Arg Val Cys Glu Leu Thr Ala Ser His Ile Val
 485 490 495
 Ala Pro Pro Tyr Val His Gly Lys Tyr Phe Tyr Cys Asn Ser Leu Phe
 500 505 510

INTERNATIONAL SEARCH REPORT

PCT/GB 03/01585

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/86

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>SOLIMAN TARIK M ET AL: "Shuttling of the herpes simplex virus type 1 regulatory protein ICP27 between the nucleus and cytoplasm mediates the expression of late proteins." JOURNAL OF VIROLOGY, vol. 71, no. 12, December 1997 (1997-12), pages 9188-9197, XP002247080 ISSN: 0022-538X page 9195 figure 1</p> <p style="text-align: center;">--- -/-</p>	1-27

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* & * document member of the same patent family

Date of the actual completion of the international search

10 July 2003.

Date of mailing of the international search report

24/07/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Guarinos Viñals, E

INTERNATIONAL SEARCH REPORT

PCT/GB 03/01585

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	CONWAY ET AL: "Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by herpes simplex virus type 1 amplicon expressing rep and cap" JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 71, no. 11, November 1997 (1997-11), pages 8780-8789, XP002102271 ISSN: 0022-538X page 8785, right-hand column page 8788, left-hand column	1-27
A	COFFIN R S ET AL: "Gene delivery to the central and peripheral nervous systems of mice using HSV1 ICP34.5 deletion mutant vectors" GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 3, no. 10, October 1996 (1996-10), pages 886-891, XP002108600 ISSN: 0969-7128 figure 1	10,16
A	ZHANG X ET AL: "HIGH-TITER RECOMBINANT ADENO-ASSOCIATED VIRUS PRODUCTION FROM REPLICATING AMPLICONS AND HERPES VECTORS DELETED FOR GLYCOPROTEIN H" HUMAN GENE THERAPY, XX, XX, vol. 10, no. 15, 10 October 1999 (1999-10-10), pages 2527-2537, XP000906820 ISSN: 1043-0342 figure 1	9

INTERNATIONAL SEARCH REPORT

PCT/GB 03/01585

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 26 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 1-27 partially
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/GB 03 /01585

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-27 partially

Present claims 1-27 relate to a ICP27 protein defined by reference to a desirable characteristic or property, namely its capacity to allow herpes virus replication and its reduced ability to inhibit RNA splicing compared to wild type ICP27.

The claims cover all ICP27 proteins having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a very limited number of such proteins. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the protein by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the ICP27 proteins comprising the double substitutions specified in page 9, lines 9-20 of the description; R480H + S334L; R480H + V487I; R480H + V496I

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.